[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"impairment-cognitive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:impairment-cognitive":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100609896","phase-4-a-study-testing-how-well-the-drug-extract-of-ginkgo-biloba-leaves-tablets-works-for-people-with-memory-or-thinking-problems-after-a-stroke-when-added-to-standard-treatment-100609896",false,"NCT07220538","A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment","Pragmatic Open-label, Parallel-group Clinical Trial on the Effectiveness of Extract of Ginkgo Biloba Leaves Tablets as add-on to Standard of Care in Participants With Cognitive Impairment After an Acute Ischemic Stroke (GiCIIS)","GiCIIS","Inclusion Criteria:\n\n1. Male and female participants aged ≥ 55 years who gave their informed consent.\n2. Non-disabling overt acute ischemic stroke (NIHSS (National Institutes of Health Stroke Scale) ≤ 5, mRS (Modified Rankin Scale) ≤ 2 at the day of screening) confirmed by magnetic resonance imaging, and at least 7 but no longer than 14 days before baseline.\n3. Cognitive impairment (MoCA (Montreal Cognitive Assessment)) total score (corrected) \\\u003C 23 for participants with up to 12 years of education, or MoCA total score \\\u003C 22 if more than 12 years of education).\n4. Sufficient Chinese language skills to understand and respond to all interview questions, complete questionnaires and undergo neuropsychological testing.\n\nExclusion Criteria:\n\n1. Participation in another experimental drug trial at the same time or within the past 4 weeks before enrollment.\n2. Aphasia, dysarthria, apraxia or paresis of the dominant upper extremity, severe and insufficiently corrected loss of vision or hearing, severe language difficulties or any other disability that may prevent the participant from cooperating adequately in the trial or that may interfere with neuropsychological test performance.\n3. Pre-stroke cognitive impairment (16-item Informant Questionnaire on Cognitive Decline (IQCODE) score ≥ 3.3), preexisting major neurocognitive disorder (e. g., dementia due to Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia).\n4. Cardiogenic ischemic stroke, atrial fibrillation, or any other conditions that require the intake of anticoagulants.\n5. Conditions that require the administration of thrombolytics at day of Screening or Visit 1.\n6. Index acute ischemic stroke with hemorrhagic transformation.\n7. Intake of traditional Chinese medicines.\n8. Major neurological disorder, including intracranial hemorrhage, delirium, Parkinson's disease, brain tumor, alcohol-associated brain damage, infectious CNS disease, epilepsy, recent brain trauma, subdural hematoma, HIV-associated cognitive disorder, Huntington's disease, Pick's disease, Wilson's disease, normal pressure hydrocephalus, hydrocephalus, progressive supra-nuclear palsy, Creutzfeldt-Jakob disease, etc.\n9. Major depression or generalized anxiety disorder.\n10. Active malignant disease.\n11. Alcohol addiction or substance abuse.\n12. Known hypersensitivity to Ginkgo biloba, Ginkgo biloba extract or any ingredient of the drug under trial.\n13. Any circumstances that prevent the participant to be followed up at the scheduled intervals. Hospitalization of the participant for long-term treatment or nursing home placement for bedside care (assisted living facility residence or stay in a rehabilitation facility is acceptable if the participant is not bedridden and does not need general bedside nursing, and if an informant is available who sees the participant on a regular basis and accompanies him\u002Fher to the trial visits).\n14. Severe comorbidity with life expectancy \\\u003C 12 months.","ALL","55 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn if Extract of Ginkgo Biloba Leaves Tablets help improve thinking and memory in people aged 55 years and older who had an ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain). It will also look at how safe the Extract of Ginkgo Biloba Leaves Tablets are.\n\nThe main questions it aims to answer are:\n\n* Do the Extract of Ginkgo Biloba Leaves Tablets help people with memory or thinking problems after an ischemic stroke?\n* What medical problems do people have when taking the Extract of Ginkgo Biloba Leaves Tablets ? Researchers will compare people who take the Extract of Ginkgo Biloba Leaves Tablets along with their usual post-stroke treatment to people who only receive their usual post-stroke treatment.\n\nParticipants will:\n\n* Have had an ischemic stroke confirmed by MRI (Magnet Resonance Imaging, a magnetic scan that helps seeing inside the body in great detail) 7 to 14 days before joining the study\n* Take Extract of Ginkgo Biloba Leaves Tablets (240 mg per day) in addition to usual post-stroke treatment for 12 months, or receive only usual post-stroke treatment for 12 months\n* Be treated initially at hospitals across China\n* Visit the clinic 4, 26, and 52 weeks following the baseline for checkups and tests, and receive follow-up calls after 12 and 38 weeks.",[27,28],"Ischemic Stroke Hospitalized","Impairment, Cognitive",[30,31],"Acute ischemic stroke","Cognitive Impairment","RECRUITING","2026-04-22",{"date":35,"type":36},"2026-04-23","ACTUAL",{"date":38,"type":36},"2025-11-28",{"date":40,"type":21},"2027-12-31",{"name":42,"class":43},"Dr. Willmar Schwabe GmbH & Co. KG","INDUSTRY",30,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100615506","neurobehavioral-changes-following-spaceflight-stressors-100615506","NCT07293494","Neurobehavioral Changes Following Spaceflight Stressors","NeuroSTAR","Inclusion Criteria:\n\n* Age between 25-60 years.\n* Free of psychological, psychiatric or physical conditions that preclude participation.\n* BMI between 18.5 and 35.\n* Self-reported regular sleep schedule; able to maintain their sleep schedule during the course of the study.\n* Self-reported sleep duration of 6-8.5 h per night (verified by daily logs).\n* Ability to read\u002Fwrite English.\n* Able to stand unassisted for up to 10 minutes at a time and able to lift arms above head.\n\nExclusion Criteria:\n\n* Alcohol or drug abuse in the past year based upon history and urine toxicology screen.\n* Potential alcohol abuse or heavy drinking in the past year, based on self-report (AUDIT-C Q2 score above 1 or Q3 score above 2).\n* Alcohol-naive based on self-report (AUDIT-C Q1 score of 0).\n* Allergies, conditions or circumstances that preclude alcohol consumption, including use of medication or supplements (prescription or over the counter) that could interfere with study participation or make it hazardous for a subject to partake (e.g., anticholinergics; antipsychotics; lithium; psychotropic drugs not otherwise specified), or for which alcohol consumption should be limited or avoided (e.g. items identified on NIAAA's 'Harmful Interactions' list).\n* Cultural or personal beliefs that preclude alcohol consumption.\n* Body Mass Index ≤18.5 or ≥ 35.\n* Current smoker\u002Ftobacco user or using nicotine replacement therapy. Those that have been nicotine-free for ≥ 30 days may be included.\n* Excessive caffeine consumption (\\> 650mg\u002Fday combining all caffeinated drinks regularly consumed during the day).\n* Acute, chronic, or debilitating medical conditions, major Axis I psychiatric illness based on history, physical exam, blood and urine chemistries; or self-reported history of neurological, psychiatric, or other medical condition that precludes participation, such as nervous system disorders, dementia, chronic migraines, or epilepsy; panic, bipolar or schizoaffective disorder; sleep disorders including insomnia, narcolepsy and obstructive sleep apnea; liver, kidney or heart disease, hypertension; infectious diseases; diabetes; or any other conditions for which medical monitoring is advised and which may require medications and\u002For lifestyles that preclude alcohol consumption and\u002For sleep disruption.\n* Current depression as determined on the Beck Depression Inventory (Beck, 1996), by either a total score of 19 or higher or a response greater than 0 on Q9 (suicidality).\n* Cardiovascular, gastrointestinal, or musculoskeletal problems, or other major conditions such as organ failure, cancer or patients requiring oxygen.\n* Prior history or diagnosis of any sleep disorder including Obstructive Sleep Apnea (AHI ≥15 events\u002Fhour) - from ambulatory or in lab polysomnography; Restless legs syndrome or periodic limb movement disorder; Insomnia; Parasomnia; High Risk of OSA based on STOP-BANG Questionnaire (\"yes\" on at least 4 of 8 questions); High Risk of Restless Legs Syndrome (RLS) based on Cambridge-Hopkins Screening questionnaire; High Risk of Insomnia based on Insomnia Severity Index (score of 22 or higher).\n* Current use or use within the past month of a prescription or over-the-counter sleep medication or stimulant (based on self-report or review with a study clinician).\n* History of potential MRI contraindications, including: tinnitus; sensorineural hearing loss \\> 30 dB; pace maker or internal defibrillator; metallic implants (e.g. orthopedic plates after bone fractures, joint replacements, surgical staples or clips, artificial heart valves, stents, cava filters); metallic splinters (e.g. after an accident or due to war injury); non-removable dental brace; Tattoo (some tattoo inks contain metallic particles); permanent make-up; non-MRI compatible intrauterine contraceptive device; cochlear implant (implanted hearing device); medication pump; acupuncture needle; other foreign bodies\u002Fobjects which are non-removable; pregnancy (or its possibility); previous brain and\u002For heart surgery.\n* History of severe motion sickness, based on self-report or driving simulator response.\n* Pregnant or currently breast feeding. People that menstruate will have a pregnancy test performed via urine sample during screening, as those that are currently pregnant are unable to participate in the study.\n* Individuals who self-report severe contact dermatitis or allergy to bandages, silicone, nickel or silver.\n* Currently working night, swing, split or rotating shift.\n* Planned travel across more than one time zone within 7 days of the scheduled study start date.\n* Habitual daytime napping.",true,"25 Years","60 Years",{"count":56,"type":21},56,[58],"NA","This study aims to investigate the impairing effects of known central nervous system (CNS) stressors in a controlled environment in order to predict and mitigate analogous risks in spaceflight. Up to 56 healthy individuals aged 25-60 will spend approx. 110 hours in a laboratory, where they will be exposed to 27 hours of sleep deprivation and will consume alcohol to reach a BAC of 0.08 on a separate day. They will perform cognitive and sensorimotor tasks and undergo MRIs and blood draws.",[61,62,63,28],"Stressor, Individual","Alcohol Impairment","Sleep Deprivation","NOT_YET_RECRUITING","2025-12-19",{"date":67,"type":36},"2025-12-29",{"date":69,"type":21},"2026-06",{"date":71,"type":21},"2029-12",{"name":73,"class":74},"University of Pennsylvania","OTHER"]